SK Bioscience Co Ltd
KRX:302440
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
35 850
60 100
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
SK Bioscience Co Ltd
Total Current Assets
SK Bioscience Co Ltd
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
SK Bioscience Co Ltd
KRX:302440
|
Total Current Assets
₩1.6T
|
CAGR 3-Years
-5%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Total Current Assets
₩5.5T
|
CAGR 3-Years
21%
|
CAGR 5-Years
18%
|
CAGR 10-Years
18%
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Total Current Assets
₩691.6B
|
CAGR 3-Years
44%
|
CAGR 5-Years
42%
|
CAGR 10-Years
21%
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Current Assets
₩441.8B
|
CAGR 3-Years
37%
|
CAGR 5-Years
41%
|
CAGR 10-Years
33%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Total Current Assets
₩130.1B
|
CAGR 3-Years
32%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Total Current Assets
₩39.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
SK Bioscience Co Ltd
Glance View
SK Bioscience Co Ltd., a remarkable enterprise carved out of the South Korean corporate landscape, operates at the dynamic intersection of biotechnology and pharmaceuticals. A part of the larger SK Group, one of Korea's leading conglomerates, the company was officially established in 2018 from SK Chemicals' life sciences division. Its primary focus is on developing and manufacturing vaccines, serving both public health needs locally and globally. The company has swiftly gained prominence for its role in the COVID-19 pandemic, particularly with the production of vaccines in collaboration with significant players such as AstraZeneca and Novavax. This strategic engagement loop has positioned SK Bioscience not only as a critical player in health crises management but also as a pivotal contributor to global health security. At the heart of SK Bioscience's business model is its ability to leverage cutting-edge research and robust manufacturing capabilities. The firm generates revenue through various channels, including product sales of its vaccines and other pharmaceuticals, contract manufacturing services, and partnerships with global entities, allowing it a diversified income stream. Its adeptness in innovation, underpinned by a strong R&D framework, ensures a steady development pipeline, supporting long-term growth ambitions. Through these strategic activities, SK Bioscience aligns itself with the SK Group’s broader commitment to social value and environmental, social, and governance (ESG) principles, fortifying its reputation as a company that not only seeks financial success but also endeavors to wield a positive global impact.
See Also
What is SK Bioscience Co Ltd's Total Current Assets?
Total Current Assets
1.6T
KRW
Based on the financial report for Dec 31, 2024, SK Bioscience Co Ltd's Total Current Assets amounts to 1.6T KRW.
What is SK Bioscience Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
56%
Over the last year, the Total Current Assets growth was 14%. The average annual Total Current Assets growth rates for SK Bioscience Co Ltd have been -5% over the past three years , 56% over the past five years .